aibio
Financings ·
Assembly Biosciences sets up $75,000,000 at-the-market program with Jefferies
Jefferies will earn up to 3.0% of gross proceeds. The stock last sold at $16.65 before the agreement.
ASMB Assembly Biosciences, Inc.
Assembly Biosciences (ASMB) news ASMB offering news
Latest Assembly Biosciences news
We have not published a story on Assembly Biosciences yet. When there is news, it will appear here.
What Assembly Biosciences does
Assembly Biosciences is a biotechnology company developing therapeutics for serious viral diseases. Its clinical-stage pipeline includes two long-acting helicase-primase inhibitors (HPIs) for recurrent genital herpes, an orally bioavailable hepatitis delta virus (HDV) entry inhibitor, and a next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV). Its pipeline also includes an oral broad-spectrum non-nucleoside polymerase inhibitor for transplant-associated herpesviruses, which is undergoing studies to enable a regulatory filing. In December 2025, Gilead Sciences, Inc. exercised its option under the Gilead Collaboration to license the HPI program, including the ABI-1179 and ABI-5366 candidates. The company says it will decide whether to opt in to a profit-share once Gilead provides a clinical development plan and budget. Assembly is completing Phase 2 preparation activities for ABI-6250 in HDV, with Phase 2 initiation expected in the fourth quarter of 2026, and has started a structured process to find partners for ABI-4334 in HBV. The text notes that no new drugs have been approved to treat genital herpes in the United States and the EU4/UK for more than 25 years.
| Product or program | What it is | Stage |
|---|---|---|
| ABI-1179 | Long-acting helicase-primase inhibitor for recurrent genital herpes, being transitioned to Gilead | Positive Phase 1b interim results in the Phase 1a/b study (December 2025) |
| ABI-5366 | Long-acting helicase-primase inhibitor for recurrent genital herpes, being transitioned to Gilead | Positive Phase 1b interim results from the monthly dosing cohorts (December 2025) |
| ABI-6250 | Orally bioavailable hepatitis delta virus entry inhibitor | Phase 2 initiation expected in the fourth quarter of 2026 |
| ABI-4334 | Next-generation capsid assembly modulator targeting hepatitis B virus; partnering sought | Positive Phase 1b topline results (June 2025) |
| ABI-7272 | Oral broad-spectrum non-nucleoside polymerase inhibitor for transplant-associated herpesviruses | Undergoing studies to enable a regulatory filing |
Assembly Biosciences annual financials
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $72.3 million | $28.5 million |
| Research and development | $64.8 million | $55.9 million |
| Net income (loss) | -$6.1 million | -$40.2 million |
| Cash from operations | -$41.1 million | -$51.1 million |
| Cash and equivalents | $58.5 million | $38.3 million |
| Short-term investments | $189.7 million | $73.7 million |
Questions about Assembly Biosciences
Has Assembly Biosciences raised money recently?
Our latest story on this, dated Nov 7, 2024: "Assembly Biosciences sets up $75,000,000 at-the-market program with Jefferies". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of Assembly Biosciences?
Assembly Biosciences, Inc. trades under the ticker ASMB on NASDAQ.
Where is Assembly Biosciences listed?
Assembly Biosciences, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:V7B; LS:A402CB; LSX:A402CB.
What is the SEC CIK of Assembly Biosciences?
The SEC Central Index Key (CIK) for Assembly Biosciences, Inc. is 1426800. Its filings are on SEC EDGAR.
How many shares does Assembly Biosciences have outstanding?
20,360,596 shares as of 2026-08-07, per the cover page of its 10-Q filed 2026-08-13.
Which country or territory is Assembly Biosciences listed under?
Our directory records Assembly Biosciences, Inc. under United States.
What does Assembly Biosciences do?
Our directory classifies Assembly Biosciences, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
What is the ISIN of Assembly Biosciences?
The ISIN recorded for Assembly Biosciences, Inc. is US0453962070.
Does aibio.space cover Assembly Biosciences?
aibio.space lists Assembly Biosciences, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Assembly Biosciences incorporated?
SEC records list its state or country of incorporation as DE.
What does Assembly Biosciences develop?
Assembly Biosciences is a biotechnology company developing therapeutics for serious viral diseases. Its clinical-stage pipeline includes two long-acting helicase-primase inhibitors (HPIs) for recurrent genital herpes, an orally bioavailable hepatitis delta virus (HDV) entry inhibitor, and a next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV).
What is ABI-1179 from Assembly Biosciences?
ABI-1179: Long-acting helicase-primase inhibitor for recurrent genital herpes, being transitioned to Gilead Stage: Positive Phase 1b interim results in the Phase 1a/b study (December 2025).
What is ABI-5366 from Assembly Biosciences?
ABI-5366: Long-acting helicase-primase inhibitor for recurrent genital herpes, being transitioned to Gilead Stage: Positive Phase 1b interim results from the monthly dosing cohorts (December 2025).
What was Assembly Biosciences's revenue last year?
$72.3 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Is Assembly Biosciences profitable?
Assembly Biosciences, Inc. reported a net loss of $6.1 million for the fiscal year ended Dec 31, 2025, and used $41.1 million of cash in operations, per its annual report to the SEC.
Investor discussion: Assembly Biosciences
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
- Mergers
Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 2.01,9.01). Source
- Distress
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. Source
- Financings
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,9.01). Source
- Distress
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. Source
- Financings
Reported a financing. SEC Form 8-K (Items 1.01,9.01). Source
Stock chart
SEC filings and registration
- SEC name
- Assembly Biosciences, Inc.
- CIK
- 1426800
- Industry (SIC)
- Pharmaceutical Preparations (2834)
- US tickers
- ASMB (Nasdaq)
- State or country of incorporation
- DE
- Fiscal year ends
- December 31
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Business address
- TWO TOWER PLACE, SOUTH SAN FRANCISCO, CA, 94080
- Phone
- (833) 409-4583
- Shares outstanding
- 20,360,596 as of 2026-08-07 (10-Q filed 2026-08-13)
- Former names
- VENTRUS BIOSCIENCES INC
Recent filings
Listing details
- Company
- Assembly Biosciences, Inc.
- Ticker
- ASMB
- Listing
- NASDAQ
- Country or territory
- United States
- Business scope
- Pharmaceuticals: Major
- ISIN
- US0453962070
- Other listed symbols
- GETTEX:V7B; LS:A402CB; LSX:A402CB
- Last quote in directory
- 2026-10-21
- Directory source
- Listing page
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction